Abstract
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
HIV infection in older patients
10.1086/374871 · 2003
HIV infection and aging: mechanisms to explain the accelerated rate of progression in the older patient
10.1016/s0047-6374(97)01888-5 · 1997
Progress in HIV therapeutics and the challenge of adherence to antiretroviral therapy
10.1016/s0891-5520(05)70139-2 · 2000
10.1001/jama.288.2.222
10.1001/jama.288.2.222
Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure
10.1097/00042560-200007010-00007 · 2000
Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
10.1097/00002030-200005050-00006 · 2000
The cost of HIV treatment and care. A global review
10.2165/00019053-200119010-00002 · 2001
Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints: the SEROCO Cohort (1988–1994)
10.1093/ije/26.6.1340 · 1997
Thymic involution and HIV progression
10.1016/s0167-5699(99)01516-9 · 1999
Mitochondrial toxicity induced by nucleoside analogue reverse-transcriptase inhibitors is a key factor in the patogenesis of antiretroviral therapy-related lipodystrophy
10.1016/s0140-6736(99)06102-4 · 1999
Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration
10.1046/j.0306-5251.2001.01452.x · 2001
Human immunodeficiency virus infection in elderly patients
10.1097/00007611-200194040-00008 · 2001
Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection
10.1086/318078 · 2001
Statins and fibrates for the treatment of hyperlipidemia in HIV-infected patients receiving HAART
10.1097/00002030-200304110-00010 · 2003
Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy
10.1016/s0924-8579(03)00100-6 · 2003
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
10.1097/00002030-199807000-00003 · 1998
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
10.1097/00002030-200001280-00001 · 2000
Unresolved referenced work
Kept as external metadata until matched
Race, sex, drug use, and progression of human immunodeficiency virus disease
10.1056/nejm199509213331202 · 1995
Factors affecting adherence to antiretroviral therapy
10.1086/313849 · 2000
Newly diagnosed HIV infection in an octgenarian: the elder are not “immune”
10.1093/ageing/32.3.353 · 2003
Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
10.1086/315334 · 2000
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
10.1001/jama.283.2.205 · 2000
Evidence for thymic function in the elderly
10.1016/s0264-410x(99)00499-5 · 2000
Changes in thymic function with age and during the treatment of HIV infection
10.1038/25374 · 1998
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adults AIDS Clinical Trial Group Cardiovascular Disease Focus Group
10.1086/317429 · 2000
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial
10.1016/s0140-6736(98)12291-2 · 1999
Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic
10.1097/00002030-200003310-00012 · 2000
Correlates of service utilization among midlife and older adults with HIV/AIDS: the role of age in equation
10.1177/08964302014003001 · 2002
Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies
1999
Salvage antiretroviral therapy
2000
A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection
10.1089/08892220050195775 · 2000
The cost effectiveness of combination antiretroviral therapy for HIV disease
10.1056/nejm200103153441108 · 2001
Costs of HIV medical care in the era of highly active antiretroviral therapy
10.1097/00002030-199905280-00013 · 1999
Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy
10.1097/00042560-200106010-00009 · 2001
The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
10.1097/00002030-200003100-00014 · 2000
Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy
10.1097/00002030-200108170-00017 · 2001
Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
10.1097/00002030-200001280-00009 · 2000
Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review
10.1097/00042560-200010001-00002 · 2000
Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
10.1056/nejm199709113371102 · 1997
Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy
10.1084/jem.190.5.725 · doi-reference
Overlooked, ignored and forgotten: older women at risk for HIV infection and AIDS
10.1177/0164027598206007 · doi-reference
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodefiency virus type 1-infected persons
10.1086/314675 · doi-reference
Stavudine and the peripheral nerve in HIV-1 infected patients
10.1007/s004150050336 · doi-reference
Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume
10.1097/00002030-200002180-00007 · doi-reference
Incidence of liver toxicity in HIV-infected patients receiving isolated dual nucleoside analogue antiretroviral therapy
10.1097/00126334-200308010-00019 · doi-reference
10.1086/313848
10.1086/313848 · doi-reference
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
10.1097/00002030-200003100-00005 · doi-reference
Elevated lactate levels in hospitalized persons with HIV infection
10.1089/088922201750063106 · doi-reference
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
10.1056/nejm199912163412501 · doi-reference
The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load
10.1016/s0163-4453(98)94351-1 · doi-reference
Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine and ritonavir therapy
10.1086/315169 · doi-reference
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response
10.1097/00042560-200003010-00002 · doi-reference
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in Nwe York City
10.1086/343048 · doi-reference
Understanding delay to medical care for HIV infection: the long-term non-presenter
10.1097/00002030-200101050-00012 · doi-reference
Fat redistribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study
10.1097/00002030-200001070-00005 · doi-reference
Recurrent “migrainelike” episodes in patients with HIV disease
10.1046/j.1526-4610.1997.3707443.x · doi-reference
Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study
10.1097/00042560-199801001-00005 · doi-reference
Mortality for liver disease in patients with HIV infection: a cohort study
10.1097/00042560-200007010-00003 · doi-reference
Function of the thymus in HIV-infected adults
10.1001/jama.282.3.219 · doi-reference
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
10.1056/nejm199810293391802 · doi-reference
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
10.1161/01.cir.100.7.700 · doi-reference
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
10.7326/0003-4819-133-1-200007040-00004 · doi-reference
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study
10.1001/archinte.160.8.1123 · doi-reference
Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART
10.1016/s0166-3542(00)00062-0 · doi-reference
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
10.1056/nejm199803263381301 · doi-reference
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy
10.1097/00002030-199902040-00008 · doi-reference
Quality of life in maintenance vs. prolonged induction therapy for HIV
10.1001/jama.284.2.178 · doi-reference
Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency type 1-infected patients: the changes in opportunistic prophylaxis study
10.1086/315471 · doi-reference
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
10.1097/00002030-200101050-00002 · doi-reference
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
10.1086/314703 · doi-reference
Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
10.1097/00042560-200001010-00005 · doi-reference
Principles and practice of HIV-protease inhibitor pharmacoenhancement
10.1046/j.1468-1293.2001.00063.x · doi-reference
Cost effectiveness of combination HIV therapy: three years later
10.2165/00019053-200017040-00002 · doi-reference
Reasons for modification and discontinuation of antiretroviral therapy. Results from a single treatment centre
10.1097/00002030-200101260-00007 · doi-reference
Lactic acidosis and hepatic steatosis associated with use of stavudine administration: report of four cases
10.7326/0003-4819-133-3-200008010-00010 · doi-reference
Management of the adverse effects of antiretroviral therapy and medication adherence
10.1086/313859 · doi-reference
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
10.1097/00002030-199905070-00009 · doi-reference
A Frequency, risk factors, and features of hyperlactatemia in a large number of patients undergoing antiretroviral therapy
10.1097/00002030-200309260-00019 · doi-reference
Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly
10.1097/00126334-200305010-00016 · doi-reference